Third-Generation Antipsychotics: What Are They?

Third-generation antipsychotics are a class of psychiatric medications defined by their ability to partially activate dopamine receptors rather than simply blocking them, which is what older antipsychotics do. The prototype and first drug approved in this group is aripiprazole, which came to market in the early 2000s and was joined over the following two decades by brexpiprazole, cariprazine, and lumateperone, among others. The distinction from earlier generations matters because partial agonism changes not just how these drugs treat psychosis but also which side effects patients face, and those trade-offs shape real decisions about treatment.

How the Three Generations Differ

The original antipsychotics, drugs like chlorpromazine and haloperidol, work by powerfully blocking dopamine D2 receptors throughout the brain. That blockade controls psychotic symptoms, but it also strips dopamine signaling from brain areas where you actually need it, causing stiffness, tremors, and involuntary movements collectively known as extrapyramidal symptoms. These first-generation drugs also drive up prolactin, a hormone that can cause breast swelling and menstrual disruption, because dopamine normally keeps prolactin in check.¹

Second-generation antipsychotics, sometimes called atypicals, were an improvement. Drugs like clozapine, olanzapine, risperidone, and quetiapine still block D2 receptors but also block serotonin 5-HT2A receptors, which appears to reduce the neurological side effects. The trade-off was metabolic: many second-generation drugs cause substantial weight gain, raise blood sugar, and worsen cholesterol profiles. That created a new clinical headache, since people with serious mental illness already face elevated cardiovascular risk.

Third-generation antipsychotics took a fundamentally different approach to the dopamine receptor. Instead of simply blocking D2, they partially activate it. Think of it like a dimmer switch rather than an on-off switch. When dopamine activity is too high, as it appears to be in the brain circuits driving psychotic symptoms, a partial agonist competes with dopamine and dials the signal down. When dopamine activity is too low, as it may be in circuits governing motivation and movement, the same drug provides a mild boost. That dual action is why these drugs are sometimes called dopamine system stabilizers.

Which Drugs Count as Third Generation

There is no universally agreed-upon roster, and the boundaries of the category have gotten fuzzier as newer drugs have arrived with increasingly complex pharmacology. Aripiprazole is the undisputed founding member. After that, the list typically includes brexpiprazole (a close chemical relative of aripiprazole), cariprazine (which has unusually strong affinity for D3 receptors), and lumateperone (which modulates serotonin, dopamine, and glutamate simultaneously).² Some reviews also include lurasidone, pimavanserin, iloperidone, and roluperidone, though not everyone agrees these belong in the same pharmacological bucket. Lurasidone, for example, acts more like a traditional D2 antagonist with serotonergic modulation, making its classification debatable.

What unites the core group is the partial-agonist mechanism at D2 receptors, though each drug layers on its own receptor profile. Cariprazine stands out for its preferential binding to D3 receptors. In brain-imaging studies of people with schizophrenia, even the lowest clinical dose of cariprazine occupied roughly three-quarters of D3 receptors while occupying under half of D2 receptors, with about a threefold difference in the drug concentrations needed to reach each target.³ That D3 preference may explain why cariprazine seems particularly effective for the motivational and emotional withdrawal symptoms that other antipsychotics largely leave untouched.

Lumateperone stands further from the pack. It modulates serotonin, dopamine, and glutamate at the same time, hitting pathways that most other antipsychotics ignore entirely.⁴ That multimodal profile reflects a broader trend in third-generation design: rather than hitting one receptor harder, these drugs try to fine-tune several systems at once.

Why Partial Agonism Changes the Side-Effect Picture

Aripiprazole binds to D2 receptors with extremely high affinity and at therapeutic doses occupies up to 95 percent of D2 receptors in the brain’s movement-control areas. With an older full-blocker antipsychotic, that level of occupancy would almost guarantee severe movement side effects. Yet aripiprazole causes relatively few of those problems, because it still lets the receptor fire at a fraction of its full capacity rather than silencing it completely.⁵ Research into the molecular details of this has shown that aripiprazole interacts with a secondary binding pocket on the D2 receptor that fine-tunes how much activation it delivers, a mechanism that was not appreciated when the drug was first developed.⁶

Lab studies have confirmed that aripiprazole’s intrinsic activity at D2 receptors is genuinely lower than that of earlier partial-agonist compounds that failed as antipsychotics. Drugs like terguride and 3-PPP showed two to three times more activation at certain D2 signaling pathways, and none of them worked well enough clinically. Aripiprazole’s success appears to depend on hitting a narrow sweet spot: enough activation to prevent movement side effects, but not so much that it fails to dampen psychotic symptoms.⁷

Metabolic and Hormonal Advantages

One of the strongest selling points for third-generation drugs is what they do not do to your metabolism. A large network analysis comparing 18 antipsychotics head to head found no evidence that aripiprazole or cariprazine caused weight gain compared with placebo. The same analysis found no significant change in total cholesterol or LDL cholesterol with aripiprazole, cariprazine, or lurasidone. By contrast, olanzapine and clozapine, both second-generation stalwarts, ranked among the worst for weight gain, cholesterol increases, and BMI changes. Cariprazine actually came out as the best-ranked drug for total cholesterol and LDL cholesterol effects.⁸ Brexpiprazole was an exception within the third-generation group: it did show evidence of weight gain in that same analysis, reminding us that the “third-generation” label does not guarantee metabolic neutrality across the board.

The hormonal picture is similarly favorable. Because partial agonists still deliver some dopamine signaling in the pituitary gland, they tend not to raise prolactin the way full blockers do. Aripiprazole usually does not elevate prolactin at all and is sometimes added to other antipsychotics specifically to bring prolactin levels back down.⁹ Third-generation drugs as a class are generally considered the first-line choice when prolactin-related side effects are a concern.¹⁰

Movement Side Effects Are Reduced but Not Gone

Across all antipsychotics, movement-related side effects remain common. A meta-analysis of observational studies estimated that roughly one in five people on antipsychotics develops drug-induced parkinsonism, about one in nine experiences akathisia (a distressing inner restlessness), and about one in fourteen develops tardive dyskinesia (involuntary repetitive movements).¹¹ Third-generation drugs bring those numbers down, but they do not eliminate them. Akathisia in particular remains a meaningful problem with cariprazine, though it occurs less frequently than with first-generation drugs.¹² Aripiprazole itself can cause a restless, agitated feeling early in treatment that sometimes gets mistaken for worsening illness rather than a drug side effect.

A review of third-generation drugs in first-episode schizophrenia found that they may match older antipsychotics in overall effectiveness while offering fewer extrapyramidal symptoms and some improvement in cognitive outcomes.¹³ That “may match” language is deliberate. The evidence base for many of these newer drugs is still thinner than what exists for second-generation workhorses like risperidone or olanzapine, and head-to-head comparisons are not as plentiful as clinicians would like.

Uses Beyond Schizophrenia

Third-generation antipsychotics have carved out a significant role in mood disorders. Aripiprazole is approved as an add-on treatment for major depression that has not responded adequately to antidepressants alone, and both aripiprazole and cariprazine are used to treat manic episodes in bipolar I disorder. For bipolar depression, which is historically harder to treat than mania, lurasidone, cariprazine, and lumateperone have all demonstrated meaningful antidepressant effects. Aripiprazole and lurasidone also have evidence supporting their use in preventing bipolar recurrence over the long term.¹⁴

Aripiprazole has also accumulated clinical experience in irritability associated with autism, Tourette syndrome in children, and as augmentation therapy in obsessive-compulsive disorder, though these uses vary by country and regulatory status. The general trend is that the favorable side-effect profile of third-generation drugs has made clinicians more comfortable prescribing them across a broader range of conditions than was typical for earlier antipsychotic generations.

Quality of Life and Real-World Outcomes

Symptom control on a rating scale does not always translate into a person actually feeling better or functioning more independently. Among second- and third-generation oral antipsychotics, aripiprazole and lurasidone have been associated with the highest levels of improvement in quality of life across multiple studies.¹⁵ That finding aligns with what you would expect from drugs that cause less weight gain, less sedation, and fewer hormonal disruptions, since all of those side effects directly erode how people feel about their daily lives.

A year-long naturalistic study comparing brexpiprazole and aripiprazole in people with schizophrenia found that both drugs improved symptoms significantly, but brexpiprazole produced a somewhat larger reduction in overall psychotic symptoms over the 12 months.¹⁶ Whether that advantage persists across larger and more diverse populations is still being studied, but it suggests that within the third-generation class itself, meaningful differences exist between drugs.

Long-Acting Injectable Versions

One of the biggest practical challenges in treating schizophrenia is that people sometimes stop taking their medication, often because they feel better and assume they no longer need it, or because side effects make the daily pill unpleasant. Long-acting injectable formulations address this by delivering weeks or months of medication in a single shot. Aripiprazole is available as a long-acting injectable (both a monthly formulation and a longer-acting lauroxil version), and paliperidone palmitate is similarly available, though the latter is a second-generation drug.

The evidence for injectables is striking. In one study, switching from oral to injectable antipsychotics reduced average hospitalization days from about ten to near zero and cut the number of relapses over three years by roughly 40 percent in treatment-compliant patients.¹⁷ A large study in a Swedish national registry found that long-acting injectables, compared with oral antipsychotics, were associated with roughly half the rate of psychiatric hospitalizations and a substantially lower rate of suicide attempts.¹⁸ The availability of aripiprazole in injectable form gives patients a third-generation option that combines the partial-agonist mechanism with the adherence benefits of a long-acting formulation.

The Switching Problem

Moving a patient from a full-blocker antipsychotic to a partial agonist like aripiprazole is not always smooth. The issue is something called dopamine supersensitivity. When a strong D2 blocker has been used for a long time, the brain compensates by increasing the number or sensitivity of D2 receptors. Withdraw the blocker and introduce a partial agonist, and those upregulated receptors suddenly receive more stimulation than they are used to, which can trigger a temporary worsening of psychosis, agitation, or mania.¹⁹

A retrospective study of 264 patients switched to aripiprazole found that those with a history of dopamine supersensitivity psychosis experienced worsening at about three times the rate of those without that history. Even among patients with no prior supersensitivity episodes, those on higher doses of their previous antipsychotic were more likely to destabilize during the switch.²⁰ The practical takeaway is that switching to a third-generation drug needs to happen gradually, with careful cross-tapering, and clinicians should be especially cautious with patients who have been on high-dose full blockers for extended periods.

Emerging Neuroprotective Interests

A more speculative but increasingly active area of research is whether third-generation antipsychotics might actually protect or repair brain tissue, not just manage symptoms. Some emerging evidence suggests that certain TGAs may positively influence brain-derived neurotrophic factor (BDNF), a protein critical for maintaining neurons and building new connections between them. The data remain limited and are drawn mostly from studies of earlier second-generation drugs, but the direction of the findings has generated genuine excitement about whether these drugs could slow or partially reverse the cognitive decline that often accompanies schizophrenia.² This remains early-stage research, and no one should choose a medication based on these preliminary signals alone.

What Comes After Third Generation

The most dramatic development in antipsychotic pharmacology in decades arrived in 2024 with the FDA approval of KarXT, a drug that works through muscarinic acetylcholine receptors rather than dopamine at all. It is the first antipsychotic approved in over 70 years that does not rely on blocking or modulating D2 receptors. Phase III trials showed it improved both the hallmark positive symptoms of schizophrenia and the harder-to-treat negative symptoms, while showing favorable metabolic safety with no clinically meaningful weight gain or blood sugar disruption.²¹

Glutamate-based approaches are also in clinical development, targeting a neurotransmitter system that has long been implicated in schizophrenia but has been difficult to drug effectively. These non-dopamine strategies do not replace third-generation antipsychotics, but they fundamentally broaden the toolkit. For patients who cannot tolerate any dopamine-modulating drug, or who have residual symptoms despite adequate dopamine-based treatment, a muscarinic or glutamatergic agent represents an entirely different therapeutic pathway. Whether these newer mechanisms eventually earn their own generational label or stand apart from the dopamine-centric numbering system remains to be seen.